- Raised funding round, Oct 2018
About
Rebiotics Rx is focused on repurposing FDA-approved antibiotics to fight antibiotic-resistant bacteria. The flagship product of Rebiotics Rx is a PEGylated Nanoliposomal-mupirocin formulation. Mupirocin has a unique mode of action, not shared by any other available antibiotic. It is active against pathogens defined as urgent and serious threats to public health, such as Neisseria gonorrhea, methicillin-resistant Staphylococcus aureus, and Streptococcus pneumonia. However, its short half-life in circulation prevents its parenteral use and limits it to topical uses. Reformulation of mupirocin by the nanoliposomes substantially increases the systemic exposure to mupirocin and prolongs its half-life, thereby enabling the parenteral activity of mupirocin and practically resulting in a novel antibiotic with demonstrated efficacy in relevant animal models.
Funding history · 1 round · — total
Q&A
- What is the current status of Rebiotics Rx?
- Rebiotics Rx is currently inactive, having ceased operations in May 2021.
- What is Rebiotics Rx's primary focus?
- Rebiotics Rx focuses on repurposing FDA-approved antibiotics to combat antibiotic-resistant bacteria.
- What is the flagship product of Rebiotics Rx?
- The flagship product of Rebiotics Rx is a PEGylated Nanoliposomal-mupirocin formulation.
- Which pathogens does Rebiotics Rx's technology target?
- Rebiotics Rx's technology targets pathogens such as Neisseria gonorrhea, methicillin-resistant Staphylococcus aureus, and Streptococcus pneumonia.
- When was Rebiotics Rx founded?
- Rebiotics Rx was founded in February 2018.
- What is the employee count for Rebiotics Rx?
- Rebiotics Rx has 1-10 employees.
- What was Rebiotics Rx's last funding round?
- Rebiotics Rx had a funding round in October 2018, with Integra Holdings as an investor.
- In which sector does Rebiotics Rx primarily operate?
- Rebiotics Rx operates primarily in the Health Tech & Life Sciences sector.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2018-2 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, May 2021 ceased to operate |